Aflibercept 2 mg biosimilars-will they lead the Anti-VEGF biosimilar world globally.
作者信息
Sharma Ashish, Woo Se Joon, Lee Christopher Seungkyu, Kumar Nilesh, Parachuri Nikulaa, Bandello Francesco, Loewenstein Anat, Kuppermann Baruch D
机构信息
Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India.
Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
出版信息
Eye (Lond). 2025 Apr;39(6):1026-1027. doi: 10.1038/s41433-025-03732-2. Epub 2025 Feb 19.
Abstract
摘要
相似文献
1
Aflibercept 2 mg biosimilars-will they lead the Anti-VEGF biosimilar world globally.阿柏西普2毫克生物类似药——它们会引领全球抗血管内皮生长因子生物类似药领域吗？
Eye (Lond). 2025 Apr;39(6):1026-1027. doi: 10.1038/s41433-025-03732-2. Epub 2025 Feb 19.
2
The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs.《生物类似药悖论：抗血管内皮生长因子生物类似药如何增加患者和整体医疗保健成本》。
Ophthalmology. 2023 Sep;130(9):966-972. doi: 10.1016/j.ophtha.2023.04.019. Epub 2023 Apr 26.
3
Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.抗血管内皮生长因子生物类似药治疗新生血管性年龄相关性黄斑变性。
Cochrane Database Syst Rev. 2024 Jun 3;6(6):CD015804. doi: 10.1002/14651858.CD015804.pub2.
4
Clinical Trials of Aflibercept Biosimilars: A Review.阿柏西普生物类似药的临床试验综述
J Ocul Pharmacol Ther. 2025 Sep;41(7):363-369. doi: 10.1089/jop.2025.0040. Epub 2025 Jun 17.
5
Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia.为下一个十年用于治疗视网膜疾病的抗 VEGF 生物类似药做准备：关注南亚。
Expert Opin Biol Ther. 2023 Jul-Dec;23(8):689-692. doi: 10.1080/14712598.2023.2239706. Epub 2023 Jul 24.
6
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.抗血管内皮生长因子（anti-VEGF）生物类似药使用变化趋势：来自印度玻璃体视网膜学会抗 VEGF 生物类似药调查的见解。
Indian J Ophthalmol. 2021 Feb;69(2):352-356. doi: 10.4103/ijo.IJO_2703_20.
7
Biosimilars in ophthalmology: "Is there a big change on the horizon?".眼科生物类似药：“即将迎来重大变革吗？”
Clin Ophthalmol. 2018 Oct 24;12:2137-2143. doi: 10.2147/OPTH.S180393. eCollection 2018.
8
Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product.生物类似药候选产品ABP 938与阿柏西普参比产品的非临床相似性
Ophthalmol Ther. 2025 Jan;14(1):85-101. doi: 10.1007/s40123-024-01043-5. Epub 2024 Nov 6.
9
Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration.深度学习辅助分析治疗抵抗性新生血管性年龄相关性黄斑变性患者从阿柏西普2毫克剂量增加至8毫克后生物标志物的变化
BMJ Open Ophthalmol. 2025 Jun 1;10(1):e002176. doi: 10.1136/bmjophth-2025-002176.
10
Noninfectious Intraocular Inflammation After Intravitreal Aflibercept.玻璃体内注射阿柏西普后的非感染性眼内炎症
JAMA Ophthalmol. 2025 May 1. doi: 10.1001/jamaophthalmol.2025.0969.
引用本文的文献
1
Recent advances in engineered exosome-based therapies for ocular vascular disease.基于工程外泌体的眼部血管疾病治疗的最新进展
J Nanobiotechnology. 2025 Jul 19;23(1):526. doi: 10.1186/s12951-025-03589-3.
本文引用的文献
1
Immunogenicity and Potential for Intraocular Inflammation of Intravitreal Anti-VEGF Drugs.玻璃体内抗VEGF药物的免疫原性及眼内炎发生可能性
Curr Ther Res Clin Exp. 2024 Mar 14;100:100742. doi: 10.1016/j.curtheres.2024.100742. eCollection 2024.
2
Biosimilar Ranibizumab and Innovator Ranibizumab-Immunogenicity Assessment and Its Impact on Safety and Efficacy.生物类似药雷珠单抗与原研雷珠单抗——免疫原性评估及其对安全性和疗效的影响
JAMA Ophthalmol. 2023 Feb 1;141(2):128-129. doi: 10.1001/jamaophthalmol.2022.5543.
3
RWC Update: Biosimilar Biologics—Need for Real World Data; Autologous Choroidal Transplantation for Wet AMD.视网膜世界大会更新：生物类似药——真实世界数据的需求；湿性年龄相关性黄斑变性的自体脉络膜移植
Ophthalmic Surg Lasers Imaging Retina. 2022 Nov;53(11):602-605. doi: 10.3928/23258160-20220930-01. Epub 2022 Nov 1.
4
Approved biosimilar ranibizumab-a global update.已批准的雷珠单抗生物类似药——全球最新情况
Eye (Lond). 2023 Feb;37(2):200-202. doi: 10.1038/s41433-022-02246-5. Epub 2022 Sep 16.
5
Ophthalmic biosimilars: Lessons from India.眼科生物类似药：来自印度的经验教训。
Indian J Ophthalmol. 2019 Aug;67(8):1384-1385. doi: 10.4103/ijo.IJO_430_19.
6
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.阿柏西普、贝伐单抗或雷珠单抗治疗糖尿病性黄斑水肿：DRCR.net方案T的近期临床相关研究结果
Curr Opin Ophthalmol. 2017 Nov;28(6):636-643. doi: 10.1097/ICU.0000000000000424.
Zotero 插件